231 related articles for article (PubMed ID: 16828529)
1. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
Schulze K; Olive C; Ebensen T; Guzmán CA
Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
[TBL] [Abstract][Full Text] [Related]
2. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
Schulze K; Medina E; Guzmán CA
Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
[TBL] [Abstract][Full Text] [Related]
4. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI.
Guzmán CA; Talay SR; Molinari G; Medina E; Chhatwal GS
J Infect Dis; 1999 Apr; 179(4):901-6. PubMed ID: 10068585
[TBL] [Abstract][Full Text] [Related]
5. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
6. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
Olive C; Clair T; Yarwood P; Good MF
Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
[TBL] [Abstract][Full Text] [Related]
7. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
Bessen D; Fischetti VA
J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296
[TBL] [Abstract][Full Text] [Related]
8. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model.
McArthur J; Medina E; Mueller A; Chin J; Currie BJ; Sriprakash KS; Talay SR; Chhatwal GS; Walker MJ
Infect Immun; 2004 Dec; 72(12):7342-5. PubMed ID: 15557665
[TBL] [Abstract][Full Text] [Related]
9. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
12. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
[TBL] [Abstract][Full Text] [Related]
13. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein.
Schulze K; Medina E; Chhatwal GS; Guzmán CA
Vaccine; 2003 May; 21(17-18):1958-64. PubMed ID: 12706684
[TBL] [Abstract][Full Text] [Related]
15. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
Bronze MS; Courtney HS; Dale JB
J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
[TBL] [Abstract][Full Text] [Related]
16. Immune responses of a liposome/ISCOM vaccine adjuvant against streptococcal fibronectin binding protein 1 (Sfb1) in mice.
McArthur J; Schulze K; Chin J; Currie BJ; Sriprakash KS; Talay SR; Chhatwal GS; Guzmán CA; Walker MJ
Indian J Med Res; 2004 May; 119 Suppl():115-20. PubMed ID: 15232175
[TBL] [Abstract][Full Text] [Related]
17. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
18. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine.
Aguila A; Donachie AM; Peyre M; McSharry CP; Sesardic D; Mowat AM
Vaccine; 2006 Jun; 24(24):5201-10. PubMed ID: 16650917
[TBL] [Abstract][Full Text] [Related]
19. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant.
Saito M; Otake S; Ohmura M; Hirasawa M; Takada K; Mega J; Takahashi I; Kiyono H; McGhee JR; Takeda Y; Yamamoto M
J Infect Dis; 2001 Mar; 183(5):823-6. PubMed ID: 11181162
[TBL] [Abstract][Full Text] [Related]
20. Immunisation against plague by transcutaneous and intradermal application of subunit antigens.
Eyles JE; Elvin SJ; Westwood A; Lebutt CS; Alpar HO; Somavarapu S; Williamson ED
Vaccine; 2004 Oct; 22(31-32):4365-73. PubMed ID: 15474730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
